Botulinum Toxins in Lower-Urinary-Tract Diseases and Dysfunctions
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 355
Special Issue Editors
Interests: urogynecology; voiding dysfunction; female sexual health; menopause
Special Issue Information
Dear Colleagues,
The first clinical use of botulinum toxin A was in the late 1970s when an ophthalmologist, Dr. Alan Scott, studied its effects on strabismus. [1] Ten years later, the first commercially available botulinum toxin, Oculinum, was FDA-approved to treat strabismus and blepharospasm. Oculinum was later renamed Botox in 1992. [1] Since then, the indications for Botox have expanded to include cervical dystonia, chronic migraine, hyperhidrosis, spasticity, and certain lower-urinary-tract diseases.
The use of botulinum toxin A for lower-urinary-tract dysfunction was first described by Dykstra et al. in 1988 for the treatment of detrusor external sphincter dyssynergia (DSD) in spinal-cord-injury patients. [2] Twelve years would pass before Schurch et al. would publish their results of intradetrusor injections of botulinum toxin A in spinal cord patients for neurogenic urge incontinence. [3] Despite the promise that botulinum toxin A showed in regard to treating lower-urinary-tract disease, it was not until 2011 that the FDA would approve Botox for the treatment of neurogenic detrusor overactivity. FDA approval for the use of Botox for idiopathic overactive bladder subsequently followed in 2013.
In addition to the FDA-approved indications for the treatment of lower-urinary-tract dysfunction with Botox, the literature regarding urologic applications of botulinum toxin also includes conditions such as benign prostatic hypertrophy, pelvic floor hypertonicity, and interstitial cystitis. This Special Issue of Toxins will include manuscripts describing the clinical experiences of botulinum toxin when treating the lower urinary tract.
References
1. Scott AB, Honeychurch D, Brin MF. Early development history of Botox (onabotulinumtoxinA). Medicine (Baltimore). 2023 Jul 1;102(S1):e32371. doi: 10.1097/MD.0000000000032371. PMID: 37499077; PMCID: PMC10374179.
2. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988;139:919–922. doi: 10.1016/s0022-5347(17)42717-0.
3. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000 Sep;164(3 Pt 1):692-7. doi: 10.1097/00005392-200009010-00018. PMID: 10953127.
Dr. Karyn S. Eilber
Dr. Jennifer T. Anger
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum toxin
- bladder
- voiding dysfunction
- lower urinary tract
- overactive bladder
- urinary incontinence
- urinary retention
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
